Americas
Worldwide
Japan
Asia Pacific
Americas
Europe, Middle East, and Africa
Mizuho Bank
Mizuho Trust & Banking
Mizuho Securities
Search
Who We Are
Our People
Diversity & Inclusion
Awards
Locations
Americas
Brazil
Mexico
Events
What We Do
Banking
Overview
Industry Coverage
Consumer + Retail
Energy
Financial Institutions
Financial Sponsors
Healthcare
Industrials
Power + Utilities + Infrastructure
Real Estate
Technology + Media + Telecom
Corporate Banking
Debt Capital Markets
Equity Capital Markets
Leveraged Finance
Mergers & Acquisitions
Private Capital Advisory
Mizuho | Greenhill International Presence
Regional Coverage
Restructuring
Risk Solutions
Banking Insights
Markets
Overview
Equities
Fixed Income
Futures + Options
Research
Overview
Treasury Services
Overview
Commercial Card Programs
Insights + News
Insights
News
Press Releases
Sustainability
Sustainability
Community
Foundation
Media Relations
Press Releases-
Media Contacts & Resources-
Careers
Client Login
Futures-
US Equity Research-
Japan Equity Research-
Global Custody-
Commercial Card Portal-
Mizuho Americas
News
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho’s Jared Holz
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho’s Jared Holz
January 24, 2025
Share This
Jared Holz, Mizuho, joins ‘Fast Money’ to talk Novo Nordisk’s recent climb.
Latest Mizuho News
See all news
The winner of the OpenAI-Anthropic race may not be the first to the IPO finish line
June 9, 2026
Mizuho Americas wins five FCS Portfolio Awards
May 20, 2026
Mizuho Head of Investment: AI is imacting every sector in the global economy
June 9, 2026
Mizuho news from around the globe
Mizuho Global News
back-to-top-blue
